|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GLCE |
Gene summary for GLCE |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GLCE | Gene ID | 26035 |
| Gene name | glucuronic acid epimerase | |
| Gene Alias | HSEPI | |
| Cytomap | 15q23 | |
| Gene Type | protein-coding | GO ID | GO:0006022 | UniProtAcc | O94923 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26035 | GLCE | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.21e-07 | -3.83e-01 | 0.0155 |
| 26035 | GLCE | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.67e-05 | -4.89e-01 | -0.1808 |
| 26035 | GLCE | HTA11_696_2000001011 | Human | Colorectum | AD | 1.84e-04 | -3.64e-01 | -0.1464 |
| 26035 | GLCE | HTA11_6818_2000001021 | Human | Colorectum | AD | 9.42e-03 | -4.62e-01 | 0.0588 |
| 26035 | GLCE | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.79e-10 | -4.51e-01 | 0.3859 |
| 26035 | GLCE | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.63e-19 | -5.76e-01 | 0.3005 |
| 26035 | GLCE | A001-C-207 | Human | Colorectum | FAP | 1.39e-03 | -2.32e-01 | 0.1278 |
| 26035 | GLCE | A015-C-203 | Human | Colorectum | FAP | 1.13e-22 | -2.83e-01 | -0.1294 |
| 26035 | GLCE | A015-C-204 | Human | Colorectum | FAP | 6.92e-07 | -3.47e-01 | -0.0228 |
| 26035 | GLCE | A014-C-040 | Human | Colorectum | FAP | 9.22e-03 | -3.90e-01 | -0.1184 |
| 26035 | GLCE | A002-C-201 | Human | Colorectum | FAP | 2.35e-09 | -2.78e-01 | 0.0324 |
| 26035 | GLCE | A002-C-203 | Human | Colorectum | FAP | 3.33e-04 | -2.35e-01 | 0.2786 |
| 26035 | GLCE | A001-C-119 | Human | Colorectum | FAP | 3.64e-05 | -4.32e-01 | -0.1557 |
| 26035 | GLCE | A001-C-108 | Human | Colorectum | FAP | 4.23e-15 | -2.15e-01 | -0.0272 |
| 26035 | GLCE | A002-C-205 | Human | Colorectum | FAP | 1.16e-17 | -3.49e-01 | -0.1236 |
| 26035 | GLCE | A001-C-104 | Human | Colorectum | FAP | 1.29e-08 | -3.68e-01 | 0.0184 |
| 26035 | GLCE | A015-C-005 | Human | Colorectum | FAP | 2.14e-02 | -2.47e-01 | -0.0336 |
| 26035 | GLCE | A015-C-006 | Human | Colorectum | FAP | 5.88e-14 | -4.40e-01 | -0.0994 |
| 26035 | GLCE | A015-C-106 | Human | Colorectum | FAP | 2.18e-07 | -2.57e-01 | -0.0511 |
| 26035 | GLCE | A002-C-114 | Human | Colorectum | FAP | 4.33e-20 | -5.94e-01 | -0.1561 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:00067901 | Colorectum | SER | sulfur compound metabolic process | 73/2897 | 339/18723 | 1.75e-03 | 1.81e-02 | 73 |
| GO:00067902 | Colorectum | MSS | sulfur compound metabolic process | 85/3467 | 339/18723 | 1.52e-03 | 1.39e-02 | 85 |
| GO:0009101 | Colorectum | FAP | glycoprotein biosynthetic process | 63/2622 | 317/18723 | 2.31e-03 | 1.86e-02 | 63 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00442725 | Esophagus | ESCC | sulfur compound biosynthetic process | 96/8552 | 148/18723 | 1.86e-06 | 2.16e-05 | 96 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:0006029 | Esophagus | ESCC | proteoglycan metabolic process | 48/8552 | 79/18723 | 4.93e-03 | 1.89e-02 | 48 |
| GO:0030166 | Esophagus | ESCC | proteoglycan biosynthetic process | 35/8552 | 56/18723 | 8.30e-03 | 2.94e-02 | 35 |
| GO:0006024 | Esophagus | ESCC | glycosaminoglycan biosynthetic process | 45/8552 | 75/18723 | 8.75e-03 | 3.08e-02 | 45 |
| GO:0006023 | Esophagus | ESCC | aminoglycan biosynthetic process | 47/8552 | 79/18723 | 9.29e-03 | 3.23e-02 | 47 |
| GO:0030201 | Esophagus | ESCC | heparan sulfate proteoglycan metabolic process | 21/8552 | 31/18723 | 1.10e-02 | 3.70e-02 | 21 |
| GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
| GO:0044272 | Liver | NAFLD | sulfur compound biosynthetic process | 28/1882 | 148/18723 | 7.52e-04 | 9.52e-03 | 28 |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:00442722 | Liver | HCC | sulfur compound biosynthetic process | 95/7958 | 148/18723 | 7.89e-08 | 1.58e-06 | 95 |
| GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
| GO:00442724 | Oral cavity | OSCC | sulfur compound biosynthetic process | 82/7305 | 148/18723 | 3.71e-05 | 3.31e-04 | 82 |
| GO:00067905 | Oral cavity | OSCC | sulfur compound metabolic process | 168/7305 | 339/18723 | 4.50e-05 | 3.84e-04 | 168 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GLCE | SNV | Missense_Mutation | c.1423G>A | p.Ala475Thr | p.A475T | O94923 | protein_coding | tolerated(0.5) | benign(0.265) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| GLCE | SNV | Missense_Mutation | c.1166N>C | p.Gly389Ala | p.G389A | O94923 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GLCE | SNV | Missense_Mutation | rs184777253 | c.202N>A | p.Val68Met | p.V68M | O94923 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-BH-A0H6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GLCE | SNV | Missense_Mutation | c.235N>G | p.Gln79Glu | p.Q79E | O94923 | protein_coding | tolerated_low_confidence(0.45) | benign(0.006) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| GLCE | SNV | Missense_Mutation | c.587N>T | p.Gly196Val | p.G196V | O94923 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BH-A1FR-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| GLCE | SNV | Missense_Mutation | novel | c.1406C>T | p.Ser469Leu | p.S469L | O94923 | protein_coding | deleterious(0) | benign(0.138) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| GLCE | insertion | In_Frame_Ins | novel | c.991_992insGTACAAATGTTAAAAAGCTTATCTGTAGCCTAC | p.Ala331delinsGlyThrAsnValLysLysLeuIleCysSerLeuPro | p.A331delinsGTNVKKLICSLP | O94923 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GLCE | insertion | Nonsense_Mutation | novel | c.227_228insGATCCAAAATTGTCCTAATACAGTTGTTCAACATTAAAA | p.Ala76_Phe77insIleGlnAsnCysProAsnThrValValGlnHisTerLys | p.A76_F77insIQNCPNTVVQH*K | O94923 | protein_coding | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GLCE | SNV | Missense_Mutation | c.1228N>A | p.Asp410Asn | p.D410N | O94923 | protein_coding | tolerated(0.66) | benign(0) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
| GLCE | SNV | Missense_Mutation | c.178N>A | p.Glu60Lys | p.E60K | O94923 | protein_coding | tolerated_low_confidence(0.25) | benign(0.018) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |